The DIAPHRAGM study: Diagnostic and prognostic biomarkers in the rational assessment of Mesothelioma

S. Tsim (Glasgow, United Kingdom), C. Kelly (Glasgow, United Kingdom), L. Alexander (Glasgow, United Kingdom), A. Shaw (Glasgow, United Kingdom), J. Paul (Glasgow, United Kingdom), R. Woodward (Glasgow, United Kingdom), J. Foster (Glasgow, United Kingdom), K. Blyth (Glasgow, United Kingdom)

Source: International Congress 2018 – Pleural disease: diagnosis, monitoring and management
Session: Pleural disease: diagnosis, monitoring and management
Session type: Oral Presentation
Number: 493
Disease area: Thoracic oncology

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
S. Tsim (Glasgow, United Kingdom), C. Kelly (Glasgow, United Kingdom), L. Alexander (Glasgow, United Kingdom), A. Shaw (Glasgow, United Kingdom), J. Paul (Glasgow, United Kingdom), R. Woodward (Glasgow, United Kingdom), J. Foster (Glasgow, United Kingdom), K. Blyth (Glasgow, United Kingdom). The DIAPHRAGM study: Diagnostic and prognostic biomarkers in the rational assessment of Mesothelioma. 493

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: